The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

Item

http://www.wikidata.org/entity/Q34110585

Q34110585

about

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients HIV infection and osteoporosis HIV infection and bone disease.Bones, Fractures, Antiretroviral Therapy and HIV.Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.An "immune barrier" is formed in the placenta by hepatitis B immunoglobulin to protect the fetus from hepatitis B virus infection from the mother.Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.Bone loss in HIV: a contemporary review.Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.The protease inhibitors and HIV-associated bone loss.Tenofovir and bone health.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.Does systemic inflammation and immune activation contribute to fracture risk in HIV?Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.Dual antiretroviral therapy for HIV infection.Management of bone mineral density in HIV-infected patients.Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?Bone Loss in HIV Infection.Protecting bone in long-term HIV positive patients receiving antiretrovirals.Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.A safety evaluation of raltegravir for the treatment of HIV.Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.The Hidden Burden of Fractures in People Living With HIV British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

P2860

Q26768591-F0908B01-DA50-4BD9-874B-7E4CBA0ABA0D Q26853139-CFE0E716-1C19-486B-9499-57F419C34B6F Q30249771-228B248A-0CA1-4D8F-8BB6-98C02DBDE687 Q34556859-3F6C2674-2B6B-494F-A96C-988058A655C1 Q36048957-72354677-2157-48E8-ADC3-E0F519C458B2 Q36102240-CE164F36-4C4A-470B-AEEE-F621E904C3BF Q36255826-F98DD3EE-B1DA-4CC9-8E9A-DB8D49CCE67F Q36282696-0D9D7A78-E427-45D5-B744-3DCF5C785AC8 Q36330955-21FC793F-673B-4615-85B0-ED93B23132F9 Q36584980-770BB264-D38E-4DC6-A46C-6F31B0D1200B Q36721002-FE694C67-03C2-4349-8603-30B2CA4B45FE Q36818259-2DAE6CCE-0A0C-4FD2-8E6F-33807C5E783A Q36833961-23A29EDE-01B5-4846-A1E9-E6352F820058 Q36868170-39982273-67B5-46FD-90C1-15B1520D80A3 Q37138907-35F295D0-49DE-4086-8A32-58FAB5256E9E Q38570500-EE91B1BA-ACC5-4407-8A74-84D5F1D1C1D0 Q38591208-0809D52C-9E4A-40A8-A9FF-06BFFD654716 Q38650067-8E690DF5-4BC6-4A84-9506-1B287E32C28B Q38670305-B2105155-3197-45CA-961F-925FD3A749C5 Q38711437-A6E6A322-E606-4C78-94D1-8F028B883460 Q38737182-2E48ED90-A7F5-4468-BF08-88E0712BCDD2 Q38835028-ACA0B349-3A50-4AD7-BFC6-6536A579E079 Q38836871-40B1BA1E-33FE-482F-847B-AE92A5B3D987 Q39453985-D46716C6-D2D0-45C9-8C9B-FB1ED9C432B7 Q40695106-EECA1B83-67BC-4DF6-BF68-A21C99A63C3B Q40725569-E779A56D-D684-460B-B4BD-FCD424C3A244 Q40846333-4572277F-9026-437A-8A07-ADB700EF0590 Q47377203-FFB9B796-B43D-4746-B81D-F994BD9FA392 Q55605012-2848C8CB-B3A2-43A8-B451-8B06AF2D80D7 Q57143538-29232235-B7EB-4BDA-AAFC-14DF816DB9B9 Q57180790-84C0C0C4-901C-4950-A0DB-EC6681D75B00

P2860

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

Item

http://www.wikidata.org/entity/Q34110585

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu